Recently in 2022, Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.), an anti-HER2 ADC, received FDA approval for the treatment of metastatic and unresectable HER-2 low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.